Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

This is the authors' abstract. We don't add key points for this paper.

Long-term continuous risankizumab treatment for up to 5 years was well tolerated and demonstrated high and durable efficacy.